ArticleNature medicine2024
Health and economic impacts of Lassa vaccination campaigns in West Africa.
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.Frontiers in immunology · 2025Trial
- Climate-driven host ecology as a framework for zoonotic disease risk: Understanding transferability across arenavirus systems.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- In silico prioritization and cheminformatics identify structurally diverse small-molecule inhibitors of Lassa virus glycoprotein-mediated membrane fusion.SLAS discovery : advancing life sciences R & D · 2026Article
- Emerging Mammarenaviruses in Wildlife: Expanding Host Range and Implications.Animals : an open access journal from MDPI · 2026Review
- Local Knowledge of Land Use Effects on Human-Rodent Interfaces in Lassa-Endemic Nigeria.EcoHealth · 2026Article
- Lessons in the Wake of a Lassa fever case in the Midwest U.S: epidemiology, management and preparedness gaps.BMC infectious diseases · 2026Review
- The socio-economic shield limits Lassa virus spillover in urban West Africa.Epidemiology and infection · 2026Article
- Health and economic burdens of emerging infectious diseases in the USA, US territories and globally.BMJ global health · 2026Article
- Decoding the human CD4Cell reports. Medicine · 2026Article
- Article
- B cell immunity to the Lassa virus glycoprotein is a correlate of vaccination-induced virus control in mice.Nature communications · 2026Article
- Screening of the Pandemic Response Box Library Identified CRM1/XPO1 as an Anti-Mammarenavirus Druggable Target.Viruses · 2026Article
- Mapping the scientific landscape of Lassa virus: a 55-year bibliometric study (1970-2025).Science in One Health · 2026Article
- A One Health trial design to accelerate Lassa fever vaccines.Nature medicine · 2026Article
- Nigeria's post-COVID-19 vaccine manufacturing ambitions: Opportunities and regional implications.Journal of public health in Africa · 2026Article
- Lassa fever: A comprehensive review of virology, clinical management, and global health implications.World journal of virology · 2025Review
- Fast-Tracking Vaccine Manufacturing: CEPI's Rapid Response Framework for the 100 Days Mission.Vaccines · 2025Article
- Ebola Virus Disease: Uniquely Challenging Among the Viral Hemorrhagic Fevers.Open forum infectious diseases · 2025Review
- Aerostability of Sin Nombre Virus Aerosol Related to Near-Field Transmission.Pathogens (Basel, Switzerland) · 2025Article
- Causal link between humid heatwaves and ischemic heart disease: assessing hospitalizations and economic burden across 955 Chinese counties.BMC medicine · 2025Article
Corrections and comments
- Update of
Authors and funding
21 authors.
Funding
Abstract
Lassa fever is a zoonotic disease identified by the World Health Organization (WHO) as having pandemic potential. This study estimates the health-economic burden of Lassa fever throughout West Africa and projects impacts of a series of vaccination campaigns. We also model the emergence of 'Lassa-X'-a hypothetical pandemic Lassa virus variant-and project impacts of achieving 100 Days Mission vaccination targets. Our model predicted 2.7 million (95% uncertainty interval: 2.1-3.4 million) Lassa virus infections annually, resulting over 10 years in 2.0 million (793,800-3.9 million) disability-adjusted life years (DALYs). The most effective vaccination strategy was a population-wide preventive campaign primarily targeting WHO-classified 'endemic' districts. Under conservative vaccine efficacy assumptions, this campaign averted $20.1 million ($8.2-$39.0 million) in lost DALY value and $128.2 million ($67.2-$231.9 million) in societal costs (2021 international dollars ($)). Reactive vaccination in response to local outbreaks averted just one-tenth the health-economic burden of preventive campaigns. In the event of Lassa-X emerging, spreading throughout West Africa and causing approximately 1.2 million DALYs within 2 years, 100 Days Mission vaccination averted 22% of DALYs given a vaccine 70% effective against disease and 74% of DALYs given a vaccine 70% effective against both infection and disease. These findings suggest how vaccination could alleviate Lassa fever's burden and assist in pandemic preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.